BioSpace News Archive

Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company, is pleased to announce that it has signed an exclusive licensing agreement with Dartmouth College to acquire the rights to a method of use patent for treating neuroendocrine cancers which express functional N-methyl-D-aspartate receptors.

Voyager Therapeutics, Inc., a gene therapy company developing life-changing treatments and next-generation platform technologies, introduced new programs in Huntington’s disease, a monogenic form of ALS, spinal muscular atrophy, and diseases linked to GBA1 mutations, all powered by its proprietary AAV capsids that have demonstrated superior transgene expression in the brain compared to AAV9 delivery in non-human primates.

ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced the commercial availability of additional vial sizes of BIVIGAM and NABI-HB, which are currently in stock and commercially available to U.S healthcare providers and patients.

Zynerba Pharmaceuticals, Inc., the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, reported financial results for the second quarter ended June 30, 2021, and provided an overview of recent operational highlights and a pipeline update.

Axsome Therapeutics, Inc., a biopharmaceutical company developing novel therapies for the management of central nervous system disorders, reported financial results for the second quarter ended June 30, 2021.

ReWalk Robotics Ltd. announced its financial results for the three and six months ended June 30, 2021.

Ginkgo Bioworks, Inc. announced that it will host a presentation reviewing results for the first six months of 2021 after the market closes on Wednesday, August 18, 2021, beginning at 4:30 p.m. ET.

Over the years, biomedical researchers have increasingly focused on developing efficient and reliable methods for precise and targeted changes to virtually any point of genome of any living cell.

MaxCyte, Inc., a leading provider of cell-engineering platform technologies, announced the signing of a clinical and commercial license with Sana Biotechnology, Inc., a company focused on creating and delivering engineered cells as medicines.

Positive topline results from the head-to-head DESTINY-Breast03 phase 3 trial showed that ENHERTU®, the Daiichi Sankyo Company, Limited and AstraZeneca HER2 directed antibody drug conjugate, demonstrated superiority over trastuzumab emtansine.